Literature DB >> 30645944

Effects of ( R)-Modafinil and Modafinil Analogues on Dopamine Dynamics Assessed by Voltammetry and Microdialysis in the Mouse Nucleus Accumbens Shell.

Jacqueline D Keighron, Juliana C Quarterman, Jianjing Cao, Emily M DeMarco, Mark A Coggiano, Apre Gleaves, Rachel D Slack, Claudio Zanettini, Amy Hauck Newman, Gianluigi Tanda.   

Abstract

Recent discoveries have improved our understanding of the physiological and pathological roles of the dopamine transporter (DAT); however, only a few drugs are clinically available for DAT-implicated disorders. Among those drugs, modafinil (MOD) and its ( R)-enantiomer (R-MOD) have been used off-label as therapies for psychostimulant use disorders, but they have shown limited effectiveness in clinical trials. Recent preclinical studies on MOD and R-MOD have led to chemically modified structures aimed toward improving their neurobiological properties that might lead to more effective therapeutics for stimulant use disorders. This study examines three MOD analogues (JJC8-016, JJC8-088, and JJC8-091) with improved DAT affinities compared to their parent compound. These compounds were investigated for their effects on the neurochemistry (brain microdialysis and FSCV) and behavior (ambulatory activity) of male Swiss-Webster mice. Our data indicate that these compounds have dissimilar effects on tonic and phasic dopamine in the nucleus accumbens shell and variability in producing ambulatory activity. These results suggest that small changes in the chemical structure of a DAT inhibitor can cause compounds such as JJC8-088 to produce effects similar to abused psychostimulants like cocaine. In contrast, other compounds like JJC8-091 do not share cocaine-like effects and have a more atypical DAT-inhibitor profile, which may prove to be an advancement in the treatment of psychostimulant use disorders.

Entities:  

Keywords:  Cocaine use disorders; FSCV; addiction; dopamine microdialysis; modafinil; nucleus accumbens shell

Mesh:

Substances:

Year:  2019        PMID: 30645944      PMCID: PMC8294083          DOI: 10.1021/acschemneuro.8b00340

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  61 in total

Review 1.  Application of microdialysis and voltammetry to assess dopamine functions in genetically altered mice: correlation with locomotor activity.

Authors:  S R Jones; R R Gainetdinov; M G Caron
Journal:  Psychopharmacology (Berl)       Date:  1999-11       Impact factor: 4.530

2.  R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse.

Authors:  Claus J Loland; Maddalena Mereu; Oluyomi M Okunola; Jianjing Cao; Thomas E Prisinzano; Sonia Mazier; Theresa Kopajtic; Lei Shi; Jonathan L Katz; Gianluigi Tanda; Amy Hauck Newman
Journal:  Biol Psychiatry       Date:  2012-04-25       Impact factor: 13.382

3.  Atypical dopamine transporter inhibitors R-modafinil and JHW 007 differentially affect D2 autoreceptor neurotransmission and the firing rate of midbrain dopamine neurons.

Authors:  Alicia J Avelar; Jianjing Cao; Amy Hauck Newman; Michael J Beckstead
Journal:  Neuropharmacology       Date:  2017-06-15       Impact factor: 5.250

Review 4.  Regulation of the Dopamine and Vesicular Monoamine Transporters: Pharmacological Targets and Implications for Disease.

Authors:  Christopher L German; Michelle G Baladi; Lisa M McFadden; Glen R Hanson; Annette E Fleckenstein
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

5.  Sigma receptor agonists: receptor binding and effects on mesolimbic dopamine neurotransmission assessed by microdialysis.

Authors:  Linda Garcés-Ramírez; Jennifer L Green; Takato Hiranita; Theresa A Kopajtic; Maddalena Mereu; Alexandra M Thomas; Christophe Mesangeau; Sanju Narayanan; Christopher R McCurdy; Jonathan L Katz; Gianluigi Tanda
Journal:  Biol Psychiatry       Date:  2010-10-15       Impact factor: 13.382

6.  Relations between stimulation of mesolimbic dopamine and place conditioning in rats produced by cocaine or drugs that are tolerant to dopamine transporter conformational change.

Authors:  Gianluigi Tanda; Su Min Li; Maddalena Mereu; Alexandra M Thomas; Aaron L Ebbs; Lauren E Chun; Valeria Tronci; Jennifer L Green; Mu-Fa Zou; Theresa A Kopajtic; Amy Hauck Newman; Jonathan L Katz
Journal:  Psychopharmacology (Berl)       Date:  2013-04-24       Impact factor: 4.530

7.  A double blind, placebo controlled trial of modafinil for the treatment of cocaine dependence without co-morbid alcohol dependence.

Authors:  Kyle M Kampman; Kevin G Lynch; Helen M Pettinati; Kelly Spratt; Michael R Wierzbicki; Charles Dackis; Charles P O'Brien
Journal:  Drug Alcohol Depend       Date:  2015-08-14       Impact factor: 4.492

8.  Real-time voltammetric detection of cocaine-induced dopamine changes in the striatum of freely moving mice.

Authors:  Erik B Oleson; Jonathan Salek; Keith D Bonin; Sara R Jones; Evgeny A Budygin
Journal:  Neurosci Lett       Date:  2009-10-12       Impact factor: 3.046

9.  Neural encoding of cocaine-seeking behavior is coincident with phasic dopamine release in the accumbens core and shell.

Authors:  Catarina A Owesson-White; Jennifer Ariansen; Garret D Stuber; Nathan A Cleaveland; Joseph F Cheer; R Mark Wightman; Regina M Carelli
Journal:  Eur J Neurosci       Date:  2009-09-04       Impact factor: 3.386

10.  A Role for Sigma Receptors in Stimulant Self Administration and Addiction.

Authors:  Jonathan L Katz; Tsung-Ping Su; Takato Hiranita; Teruo Hayashi; Gianluigi Tanda; Theresa Kopajtic; Shang-Yi Tsai
Journal:  Pharmaceuticals (Basel)       Date:  2011
View more
  11 in total

1.  Modafinil potentiates cocaine self-administration by a dopamine-independent mechanism: possible involvement of gap junctions.

Authors:  Maddalena Mereu; Takato Hiranita; Chloe J Jordan; Lauren E Chun; Jessica P Lopez; Mark A Coggiano; Juliana C Quarterman; Guo-Hua Bi; Jacqueline D Keighron; Zheng-Xiong Xi; Amy Hauck Newman; Jonathan L Katz; Gianluigi Tanda
Journal:  Neuropsychopharmacology       Date:  2020-04-27       Impact factor: 7.853

Review 2.  Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine.

Authors:  Chloe J Jordan; Jianjing Cao; Amy Hauck Newman; Zheng-Xiong Xi
Journal:  Neuropharmacology       Date:  2019-04-19       Impact factor: 5.250

3.  Evaluation of Urea-Based Inhibitors of the Dopamine Transporter Using the Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis.

Authors:  Md Ashraf-Uz-Zaman; Guangchen Ji; Dalton Tidwell; Linda Yin; Smathorn Thakolwiboon; Jie Pan; Riley Junell; Zach Griffin; Sadisna Shahi; Derek Barthels; Md Sanaullah Sajib; Paul C Trippier; Constantinos M Mikelis; Hiranmoy Das; Mirla Avila; Volker Neugebauer; Nadezhda A German
Journal:  ACS Chem Neurosci       Date:  2022-01-03       Impact factor: 5.780

4.  Structure-activity relationships for a series of (Bis(4-fluorophenyl)methyl)sulfinylethyl-aminopiperidines and -piperidine amines at the dopamine transporter: Bioisosteric replacement of the piperazine improves metabolic stability.

Authors:  JoLynn B Giancola; Alessandro Bonifazi; Jianjing Cao; Therese Ku; Alexandra J Haraczy; Jenny Lam; Rana Rais; Mark A Coggiano; Gianluigi Tanda; Amy Hauck Newman
Journal:  Eur J Med Chem       Date:  2020-08-09       Impact factor: 6.514

5.  Cocaine-induced locomotor stimulation involves autophagic degradation of the dopamine transporter.

Authors:  Maged M Harraz; Prasun Guha; Evan R Semenza; Adarsha P Malla; In Guk Kang; Young Jun Song; Luke Reilly; Isaac Treisman; Pedro Cortés; Mark A Coggiano; Vijayabhaskar Veeravalli; Rana Rais; Gianluigi Tanda; Solomon H Snyder
Journal:  Mol Psychiatry       Date:  2021-01-07       Impact factor: 15.992

6.  Neurophysiological and Neurochemical Effects of the Putative Cognitive Enhancer (S)-CE-123 on Mesocorticolimbic Dopamine System.

Authors:  Claudia Sagheddu; Nicholas Pintori; Predrag Kalaba; Vladimir Dragačević; Gessica Piras; Jana Lubec; Nicola Simola; Maria Antonietta De Luca; Gert Lubec; Marco Pistis
Journal:  Biomolecules       Date:  2020-05-18

7.  Differential Effects of Novel Dopamine Reuptake Inhibitors on Interference With Long-Term Social Memory in Mice.

Authors:  Judith Camats-Perna; Predrag Kalaba; Karl Ebner; Simone B Sartori; Harish Vuyyuru; Nilima Y Aher; Vladimir Dragačević; Nicolas Singewald; Mario Engelmann; Gert Lubec
Journal:  Front Behav Neurosci       Date:  2019-04-11       Impact factor: 3.558

8.  Synaptic Zn2+ potentiates the effects of cocaine on striatal dopamine neurotransmission and behavior.

Authors:  Juan L Gomez; Jordi Bonaventura; Jacqueline Keighron; Kelsey M Wright; Dondre L Marable; Lionel A Rodriguez; Sherry Lam; Meghan L Carlton; Randall J Ellis; Chloe J Jordan; Guo-Hua Bi; Oscar Solis; Marco Pignatelli; Michael J Bannon; Zheng-Xiong Xi; Gianluigi Tanda; Michael Michaelides
Journal:  Transl Psychiatry       Date:  2021-11-08       Impact factor: 6.222

Review 9.  Modafinil and its structural analogs as atypical dopamine uptake inhibitors and potential medications for psychostimulant use disorder.

Authors:  Gianluigi Tanda; Melinda Hersey; Briana Hempel; Zheng-Xiong Xi; Amy Hauck Newman
Journal:  Curr Opin Pharmacol       Date:  2020-09-11       Impact factor: 5.547

10.  Reinstatement of synaptic plasticity in the aging brain through specific dopamine transporter inhibition.

Authors:  Jana Lubec; Predrag Kalaba; Ahmed M Hussein; Daniel Daba Feyissa; Mohamed H Kotob; Rasha R Mahmmoud; Oliver Wieder; Arthur Garon; Claudia Sagheddu; Marija Ilic; Vladimir Dragačević; Anita Cybulska-Klosowicz; Martin Zehl; Judith Wackerlig; Simone B Sartori; Karl Ebner; Shima Kouhnavardi; Alexander Roller; Natalie Gajic; Marco Pistis; Nicolas Singewald; Johann Jakob Leban; Volker Korz; Jovana Malikovic; Roberto Plasenzotti; Harald H Sitte; Francisco J Monje; Thierry Langer; Ernst Urban; Christian Pifl; Gert Lubec
Journal:  Mol Psychiatry       Date:  2021-12       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.